FN2 Earnings Intelligence
Teva Pharmaceutical Industries Limited income statement (quarterly)
Teva Pharmaceutical Industries Limited (TEVA) Income Statement (quarterly) derived from persisted SEC financial facts.
Key Stats
USD in millions, except per-share values and percentages.
| Metric | 3/31/2025 | 6/30/2025 | 9/30/2025 | 3/31/2026 | 6/30/2026 |
|---|---|---|---|---|---|
| Market Cap | - | - | - | - | - |
| - Cash | $1,697 | $2,161 | $2,203 | $3,741 | $3,655 |
| + Debt | - | - | - | - | - |
| Enterprise Value | - | - | - | - | - |
| Revenue | $3,891 | $4,176 | $4,480 | $3,982 | $4,142 |
| % Growth | - | - | - | - | - |
| Gross Profit | $1,877 | $2,102 | $2,304 | $1,972 | $2,153 |
| % Margin | 48.2% | 50.3% | 51.4% | 49.5% | 52.0% |
| EBITDA | $763 | $706 | $1,131 | $891 | $10 |
| % Margin | 19.6% | 16.9% | 25.2% | 22.4% | 0.2% |
| Net Income | $214 | $282 | $433 | $369 | -$576 |
| % Margin | 5.5% | 6.8% | 9.7% | 9.3% | -13.9% |
| Diluted EPS | $0.18 | $0.24 | $0.37 | $0.31 | -$0.49 |
| % Growth | - | - | - | - | - |
| Operating Cash Flow | -$105 | $227 | $369 | -$40 | $411 |
| CapEx | $127 | $96 | $136 | $168 | $104 |
| Free Cash Flow | -$232 | $131 | $233 | -$208 | $307 |
Historical market capitalization is not persisted, so Market Cap and Enterprise Value remain unavailable rather than mixing today's market value into prior periods.
Income Statement
USD in millions, except per-share values and percentages.
| Metric | 3/31/2025 | 6/30/2025 | 9/30/2025 | 3/31/2026 | 6/30/2026 |
|---|---|---|---|---|---|
| Revenue | $3,891 | $4,176 | $4,480 | $3,982 | $4,142 |
| Gross Profit | $1,877 | $2,102 | $2,304 | $1,972 | $2,153 |
| EBITDA | $763 | $706 | $1,131 | $891 | $10 |
| Net Income | $214 | $282 | $433 | $369 | -$576 |
| Diluted EPS | $0.18 | $0.24 | $0.37 | $0.31 | -$0.49 |
Balance Sheet
USD in millions, except per-share values and percentages.
| Metric | 3/31/2025 | 6/30/2025 | 9/30/2025 | 3/31/2026 | 6/30/2026 |
|---|---|---|---|---|---|
| Cash & Equivalents | $1,697 | $2,161 | $2,203 | $3,741 | $3,655 |
| Short-term Debt | $421 | $464 | $24 | $2,612 | $23 |
| Long-term Debt | - | - | - | - | - |
| Total Debt | - | - | - | - | - |
Cash Flow
USD in millions, except per-share values and percentages.
| Metric | 3/31/2025 | 6/30/2025 | 9/30/2025 | 3/31/2026 | 6/30/2026 |
|---|---|---|---|---|---|
| Operating Cash Flow | -$105 | $227 | $369 | -$40 | $411 |
| Capital Expenditure | $127 | $96 | $136 | $168 | $104 |
| Free Cash Flow | -$232 | $131 | $233 | -$208 | $307 |
Ratios
USD in millions, except per-share values and percentages.
| Metric | 3/31/2025 | 6/30/2025 | 9/30/2025 | 3/31/2026 | 6/30/2026 |
|---|---|---|---|---|---|
| Revenue Growth | - | - | - | - | - |
| Gross Margin | 48.2% | 50.3% | 51.4% | 49.5% | 52.0% |
| EBITDA Margin | 19.6% | 16.9% | 25.2% | 22.4% | 0.2% |
| Net Margin | 5.5% | 6.8% | 9.7% | 9.3% | -13.9% |
| FCF Margin | -6.0% | 3.1% | 5.2% | -5.2% | 7.4% |
| Diluted EPS Growth | - | - | - | - | - |
Get the TEVA recap when the next report posts
One email per quarter with the scorecard, the market reaction and what changed on the call. No account needed.